EUCTR2020-001521-31-DE进行中（未招募）1 期
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma - LOGOS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. 12 to 80 years of age, male and female, BMI <40 kg/m2; females must be not of childbearing
- •potential or using a form of highly effective birth control.
- •2. Documented history of physician-diagnosed asthma > and/or = 1 year prior to V1.
- •3. Regularly using a stable daily ICS/LABA regimen (including a stable ICS dose) with medium-to-high ICS doses for at least 4 weeks prior to V1.
- •4. ACQ-7 total score =1.5 at Visits 1, 3, and 5 (pre-randomization).
- •5. FEV1 % (assessed as an average of the 60 and 30 minute pre-dose assessments) predicted normal at V1, 2, 3, 4, and 5 (pre-randomization)
- •Participants > and/or = 18 years of age: < 80%
- •Participants 12 to <18 years of age: < 90%
- •6. FEV1 post-albuterol at V2 or V3 (if repeat needed).
- •Participants > and/or = 18 years of age: Increase > and/or = 12% and > and/or = 200 mL.
- •Participants 12 to <18 years of age: Increase =12% either in the 12 months prior to Visit 1 or at Visit 2, or at Visit 3.
- •Note: Even if there is documented history of reversibility, all participants must be assessed for reversibility at Visit 2 (and Visit 3, if reversibility is not demonstrated at Visit 2) to provide reversibility baseline data for characterization.
- •7. Willing and, in the opinion of the Investigator, able to adjust current asthma therapy, as required by the protocol.
- •8. Demonstrate acceptable MDI/pMDI administration technique.
- •9. Received no asthma medication other than run-in BFF MDI BID and albuterol as needed during screening (except for allowed medications as defined in Table 9 and systemic corticosteroid or ICS for the treatment of an asthma exacerbation).
- •10. eDiary 14-day compliance =70% during screening (defined as completing the daily eDiary for any 10 mornings and any 10 evenings and answering Yes to taking 2 puffs of run-in BFF MDI for any 10 mornings and 10 evenings in the last 14 days prior to randomization).
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 80
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1881
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 239
排除标准
- •1. Completed treatment for respiratory infection or asthma exacerbation with systemic corticosteroids within 4 weeks of V1.
- •2a. Participants where, in the opinion of the Investigator, treatment with biological therapy for asthma would be appropriate.
- •2b. Any marketed or investigational biologics within 3 months or 5 half-lives of V1, whichever is longer and must not be used during study duration.
- •3. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking <6 months prior to V1 (including all forms of tobacco, e-cigarettes or other vaping devices, and marijuana).
- •4. Current evidence of COPD
- •5a. Oral and IV corticosteroid use (any dose) within 4 weeks of V1.
- •5b. Use of systemic corticosteroids for any other reason except for the acute treatment of severe asthma exacerbation is prohibited for the duration of the study.
- •5c. Depot corticosteroid use for any reason within 3 months of V1.
- •6. Use of LAMA as maintenance treatment, either alone or as part of an inhaled combination therapy, within 12 months prior to V1.
- •7. Use of oral beta2-agonist within 3 months of V1.
- •8. Use of any immunomodulators or immunosuppressive medication within 3 months or 5 half-lives, whichever is longer, and must not be used during the study duration.
- •9. Narrow angle glaucoma not adequately treated and/or change in vision that may be relevant, in the opinion of the Investigator, within 3 months of Visit 1.
- •10.Life-threatening asthma defined as a history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal episode(s).
- •11.Hospitalization for asthma within 2 months of Visit 1.
- •12.Known history of drug or alcohol abuse within 12 months of Visit 1.
- •13.Regular use of a nebulizer or a home nebulizer for receiving asthma medications.
- •14.Using any herbal products by inhalation or nebulizer within 4 weeks of Visit 1 and does not agree to stop during the study duration.
- •15.Participation in another clinical study with a study intervention administered in the last 30 days or 5 half-lives, whichever is longer. Any other study intervention that is not identified in the protocol is prohibited for use during study duration.
- •16.Participants with a known hypersensitivity to beta2-agonists, corticosteroids, anticholinergics, or any component of the MDI or pMDI.
- •17.Study Investigators, sub-Investigators, coordinators, and their employees or immediate family members.
- •18.For women only – currently pregnant (confirmed with positive highly sensitive pregnancy test), breast-feeding, or planned pregnancy during the study or not using acceptable contraception measures, as judged by the Investigator.
研究者
相似试验
进行中（未招募）
1 期
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with Severe Asthma Inadequately Controlled with Standard of Care.EUCTR2020-001520-34-BGAstraZeneca AB2,200
进行中（未招募）
1 期
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with Severe Asthma Inadequately Controlled with Standard of Care.Severe and inadequately controlled asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-001520-34-ITASTRAZENECA AB2,800
进行中（未招募）
1 期
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with Severe Asthma Inadequately Controlled with Standard of Care.Severe and inadequately controlled asthmaMedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2020-001520-34-BEAstraZeneca AB2,800
撤回
3 期
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS)AsthmaNL-OMON51184Astra Zeneca28
进行中（未招募）
1 期
A Variable Length Study to Evaluate the Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol inhaler in Adults and Adolescents with Severe Asthma Inadequately Controlled with Standard of Care.EUCTR2020-001521-31-PTAstraZeneca AB2,200